Navigation Links
ULURU Inc. Reports Second Quarter 2013 Financial Results
Date:8/15/2013

ting plan and a lower head count, a decrease of $88,000 in investor relations consulting and a decrease of $42,000 in insurance costs.

Other income and Other expenses

Interest expense for the second quarter of 2013 was $128,000 as compared to $31,000 for the second quarter of 2012.  The increase of approximately $97,000 is primarily attributable to costs associated with our convertible debt.

About ULURU Inc.:ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com.  For further information about Altrazeal®, please visit our website at www.altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc. (the "Company"), the advancement of licensing discussions for additional markets, the anticipated launch of Altrazeal® in various markets and countries, the demonstration of clinical benefits and cost benefits of Altrazeal®,  the completion of strategic alliances, the anticipated escalation of revenues, positive cash flows, and improved profitability in 2013, and the acceptance of Altrazeal® by medical practitioners.  When used in this press release, the words "believe," "expect" and "anticipate" and similar expressions may be indicative of forward-looking statements including without limitation statements re
'/>"/>

SOURCE ULURU Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
2. ULURU Inc. Reports First Quarter 2013 Financial Results
3. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
4. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
6. ULURU Inc. Business Update And Outlook
7. ULURU Inc. Announces Closing Of $440,000 Private Placement
8. ULURU Inc. Reports Third Quarter 2012 Financial Results
9. ULURU Inc. Announces The First Shipment Of Veterinary Product
10. ULURU Inc. Announces First Order Of Altrazeal For European Launch
11. ULURU Inc. Reports Second Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Biosafety , , , ... June 29 Remember chemistry sets, ham radio, amateur astronomy, and early ... around the world belong to the Do-It-Yourself Biology (DIYbio) community, working on everything ... treatments for diseases. , , , ...
... Ireland , June 28 Warner Chilcott plc ... IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification ... Application (ANDA) by Par for a generic version of the Company,s ASACOL ... , , ...
Cached Medicine Technology:Responsible Science for Do-It-Yourself Biologists 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Did you know ... Orange County looking for exceptional and affordable home care options which A-1 Home Care ... just a few of the credentials A-1 Home Care Agency is known ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5
... de Toulouse-Lautrec suffered, is a genetic disease characterized by ... into how joints are destroyed by arthritis. It is ... K which hampers osteoclasts (the cells that break down ... bone resorption and dense, brittle bones. , Cathepsin ...
... Patients Received Assistance with Drug Co-Pays, HOUSTON, Nov. ... a national oral oncology specialty pharmacy, has,exceeded the $10 ... co-pays since the launch of Care Advantage in August ... Advantage to be able to,increase patient access to oral ...
... 4 Mylan Inc. (NYSE: MYL ),today ... approval from the U.S. Food and Drug Administration ... Levetiracetam Tablets, 250 mg,500 mg and 750 mg. ... Keppra(R)., Robert J. Coury, Mylan,s Vice Chairman ...
... blood pressure experienced during pregnancy could be a woman,s ... heart disease the number one killer of Canadian ... Gynecology, Graeme Smith. , Called pre-eclampsia, this type ... of all pregnancies. , But because most practicing ...
... , , TUESDAY, Nov. 4 (HealthDay News) -- Children who live ... undernourished, a new study finds. , The same is true ... impact the most, said study author Dr. Michael Weitzman, chairman ... "We know that there are long-term consequences of food insecurity ...
... Secretary and other members of bipartisan,group of Capitol ... energy, transportation, trade, labor and employment,and tax policy, ... and grueling,Presidential campaign, one thing is certain: change ... with or regulated by the federal government,will face ...
Cached Medicine News:Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2Health News:Pregnancy disorder signals need to screen for heart disease 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 2Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: